Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Background: Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy. We tested ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

serotonergic and adrenergic receptors – failed to improve the positive and negative schizophrenia symptom scale (PANSS) compared to conventional therapy in patients with treatment-resistant ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

a second-generation antipsychotic often used for treatment-resistant schizophrenia, also ranked low (0.12). For reference, a significant or noticeable SMD result would be anything 0.5 or higher ...

The death of a mother at the hands of her son was described as “tragic” by a Calgary judge, who found the 32-year-old not criminally responsible.

While Cobenfy’s approval marks a significant step forward in schizophrenia treatment, questions remain about its long-term impact, particularly in addressing cognitive symptoms and its potential ...

Erin Crown, PA-C, CAQ-Psychiatry is a paid consultant of ®2024 Otsuka America Pharmaceutical, Inc. and Lundbeck, manufacturers of ABILIFY ASIMTUFII® (aripiprazole) and ABILIFY MAINTENA ...

For those who live with schizophrenia, the sound of voices — voices that no one else can hear — can be an overwhelming and persistent part of daily life. But the mystery of why these hallucinations ...